Literature DB >> 9788767

Discriminative stimulus properties of the 5-HT1A receptor agonist BAY x 3702 in the rat.

J De Vry1, K R Jentzsch.   

Abstract

The aminomethylchroman derivative BAY x 3702 (R-(-)-2-¿4-[(chroman-2-ylmethyl)-amino]-butyl¿-1,1-dioxo-benzo[d] isothiazolone HCl) has recently been characterized as a relatively selective, high affinity 5-HT1A receptor agonist with neuroprotective, anxiolytic- and antidepressant-like effects in animal models. It was the aim of the present study to further confirm its receptor binding profile in an in vivo assay. Rats were trained to discriminate BAY x 3702 (0.1 mg/kg, i.p.) from vehicle in a standard two-lever fixed ratio 10 food-reinforced procedure. All rats learned the discrimination, the median number of sessions to reach criterion being 38 (range: 22-58 sessions). Generalization tests with BAY x 3702 showed dose-dependent and complete generalization after different routes of administration; the ED50 values being: 0.030, 0.007 and 0.36 mg/kg, after i.p., i.v. and p.o. administration, respectively. Assessment of the duration of action after administration of 0.1 mg/kg BAY x 3702, i.p., resulted in a T1/2 of 65 min. Dose-dependent and complete generalization was also obtained with the 5-HT1A receptor agonists 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin, ED50 in mg/kg, i.p.: 0.086), flesinoxan (0.30), SR 57746A ((4-(3-trifluoromethylphenyl)-N-(2-(naphth-2-yl)ethyl)-1,2,3,6-tet rahydropyridine HCl, 1.0), the (+)-enantiomer of BAY x 3702 (1.3) and ipsapirone (1.8); the ED50 values being closely correlated with their respective affinities for the 5-HT1A receptor. Pretreatment with the selective 5-HT1A receptor antagonist WAY-100635 ((N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N(2-pyridinyl) cyclohexane carboxamide trihydrochloride) dose-dependently and completely blocked the discriminative effects of 0.1 mg/kg BAY x 3702 (ID50: 0.013 mg/kg, i.p.). WAY-100635, prazosin, idazoxan, raclopride, paroxetine, (-)-BAY k 8644 (methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoro-methyl-phenyl)-p yridine-5-carboxylate), ethanol, and the putative neuroprotectants MK-801 ((+)-5-methyl-10,11-dihydroxy-5H-dibenzo(a,d)cyclohepten-5,10-imin e), CNS 1102 (N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methyl-guanidine), CGS 19755 (cis-4-(phosphonomethyl) piperidine-2-carboxylic acid) and nimodipine did not induce more than 20% generalization. It is concluded that the BAY x 3702 cue is mediated by its agonistic activity at 5-HT1A receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788767     DOI: 10.1016/s0014-2999(98)00503-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspirone.

Authors:  Adam S Olsen; Christopher N Sozda; Jeffrey P Cheng; Ann N Hoffman; Anthony E Kline
Journal:  J Neurotrauma       Date:  2012-04-23       Impact factor: 5.269

2.  Potential serotonin 5-HT(1A) and dopamine D(4) receptor modulation of the discriminative stimulus effects of amphetamine in rats.

Authors:  Danuta Marona-Lewicka; David E Nichols
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 3.  Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation.

Authors:  Alexandra N Garcia; Mansi A Shah; C Edward Dixon; Amy K Wagner; Anthony E Kline
Journal:  PM R       Date:  2011-06       Impact factor: 2.298

4.  Alterations in serotonin receptors and transporter immunoreactivities in the hippocampus in the rat unilateral hypoxic-induced epilepsy model.

Authors:  Sung-Jin An; Duk-Soo Kim
Journal:  Cell Mol Neurobiol       Date:  2011-06-17       Impact factor: 5.046

5.  Acute treatment with the 5-HT(1A) receptor agonist 8-OH-DPAT and chronic environmental enrichment confer neurobehavioral benefit after experimental brain trauma.

Authors:  Anthony E Kline; Amy K Wagner; Brian P Westergom; Rebecca R Malena; Ross D Zafonte; Adam S Olsen; Christopher N Sozda; Pallavi Luthra; Monisha Panda; Jeffery P Cheng; Haris A Aslam
Journal:  Behav Brain Res       Date:  2006-12-12       Impact factor: 3.332

6.  Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Authors:  Frank G Boess; Jean de Vry; Christina Erb; Timo Flessner; Martin Hendrix; Joachim Luithle; Christoph Methfessel; Katrin Schnizler; F Josef van der Staay; Marja van Kampen; Welf-Burkhard Wiese; Gerhard König
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

Review 7.  5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.

Authors:  Jeffrey P Cheng; Jacob B Leary; Aerin Sembhi; Clarice M Edwards; Corina O Bondi; Anthony E Kline
Journal:  Brain Res       Date:  2015-11-21       Impact factor: 3.252

8.  A delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learning.

Authors:  Jeffrey P Cheng; Ann N Hoffman; Ross D Zafonte; Anthony E Kline
Journal:  Behav Brain Res       Date:  2008-07-01       Impact factor: 3.332

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.